NCT00756769 Systemic Lupus Erythematosus in Gullah Health
| NCT ID | NCT00756769 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of South Carolina |
| Condition | Systemic Lupus Erythematosus |
| Study Type | OBSERVATIONAL |
| Enrollment | 750 participants |
| Start Date | 2003-04 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 750 participants in total. It began in 2003-04 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, multiple organ involvement, and diverse clinical symptoms and immunologic manifestations. African Americans are at a disproportionately higher risk of developing SLE, develop SLE at an earlier age, and have increased morbidity and mortality compared with European Americans. Our central study hypothesis is that there are specific genetic factors that interact with environmental exposures leading to the development of SLE. The African American Gullah population from the Sea Islands of South Carolina and Georgia are unique in their genetic homogeneity with minimal non-African genetic admixture, making them an ideal cohort to address questions of environmental and genetic influence on the development and progression of SLE.
Eligibility Criteria
Inclusion Criteria: * Age 2 years and above; * Self-identified as African-American "Gullah" from the Sea Island region of South Carolina; * Have had at least 4 of the 11 diagnostic criteria for SLE as designated by the American College of Rheumatology (ACR), be a relative of a known SLE patient, or be an unrelated healthy Gullah control; * Ability to speak and understand English; * Ability and willingness to give informed consent Exclusion Criteria: * Race defined by participant as other than Black or African-American; * Being a prisoner, mentally ill patient, or institutionalized individual; * Unwilling or unable to give informed consent
Contact & Investigator
Diane L. Kamen, MD, MSCR
PRINCIPAL INVESTIGATOR
Medical University of South Carolina
Frequently Asked Questions
Who can join the NCT00756769 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, studying Systemic Lupus Erythematosus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00756769 currently recruiting?
Yes, NCT00756769 is actively recruiting participants. Contact the research team at kamend@musc.edu for enrollment information.
Where is the NCT00756769 trial being conducted?
This trial is being conducted at Charleston, United States.
Who is sponsoring the NCT00756769 clinical trial?
NCT00756769 is sponsored by Medical University of South Carolina. The principal investigator is Diane L. Kamen, MD, MSCR at Medical University of South Carolina. The trial plans to enroll 750 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.